ITRM (iterumtx.com) Net earnings per share (EPS TTM)

iterumtx.com (ITRM) - corporate logo

Despite high launch costs for new products, Iterum Therapeutics plc (ITRM) is protected by antibiotic formula patents and stringent FDA controls. The current rolling annual EPS visualizes financial stability, where -0.72 determines the latest valuation metric. The risks for Iterum Therapeutics plc (ITRM) are mitigated by the development of modern drugs for the home treatment of severe urinary tract infections, which guarantees stable demand.

ITRM (Iterum Therapeutics, plc) Net earnings per one share for the last twelve months history from 07/04/2022 to 04/11/2026

Iterum Therapeutics, plc (ITRM) - metric breakdowns and financial figures

- current quotes and average value forecast:
Price Chart Iterum Therapeutics PLC|ITRM - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Iterum Therapeutics PLC|ITRM - Full Business Value
- business book valuation details:
Book Value per Share Iterum Therapeutics|ITRM - Total Stockholders' Equity|Market Capitalization to Book Value Ratio iterumtx.com|ITRM - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Iterum Therapeutics plc|ITRM - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Iterum Therapeutics PLC|ITRM - Company Total Debt Obligations|Debt to Book Capitalization Ratio Iterum Therapeutics plc|ITRM - Long-Term Debt|Company Short-Term Debt Iterum Therapeutics|Quick Liquidity iterumtx.com
- net income and valuation multiples indicators:
ITRM - Net Financial Result|Projected Future Earnings Iterum Therapeutics plc|ITRM - Business Payback Period|Projected Price to Earnings Iterum Therapeutics, plc|ITRM - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Iterum Therapeutics plc|ITRM - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Iterum Therapeutics|ITRM - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months iterumtx.com|ITRM - Earnings growth in current year|Net earnings per share growth forecast for next year Iterum Therapeutics plc
- revenue and sales proceeds data:
ITRM - Company Sales|Company Future Sales Volume Iterum Therapeutics|ITRM - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Iterum Therapeutics plc|ITRM - Revenue Change YoY (Last 12 Months)
Fundamental company analysis:ITRM - iterumtx.com
Flagship merchandise of Iterum Therapeutics PLC

The metric is calculated as the ratio of total net income over the last four quarters to the total number of shares. This metric determines the real return on each ownership stake, capturing business consolidation phases. For Iterum Therapeutics plc (ITRM), regulatory procedure expenses are covered by reserves, which directly impacts the bottom line. By analyzing the TTM earnings per share trend, an investor assesses the balance between the market price and asset value. A local breakout of this line may be a deceptive signal.

Main competitors

SMMT - Earnings per share for the last twelve months|MRNA (Moderna) - Earnings per share for the last 12 months|PCVX: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months TARS (Tarsus Pharma)|CRMD (CorMedix Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Seres Therapeutics MCRB|Net earnings per share (EPS TTM) SPRO|Net earnings per share for the last 12 months Scynexis SCYX|AN2 Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters PYPD (PolyPid Limited)|LSB - Earnings per share for the last twelve months|Net earnings per share for the last four quarters BiomX PHGE|soligenix.com (SNGX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharma (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Corporation)